- Home
- VINP vs ARVN Comparison
VINP vs ARVN Comparison
Compare VINP & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | ARVN |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.6M | 781.0M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VINP | ARVN |
|---|---|---|
| Price | $10.53 | $10.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $14.00 | ★ $15.35 |
| AVG Volume (30 Days) | 80.0K | ★ 785.5K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | ★ 5.87% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $20.11 | N/A |
| Revenue Next Year | $16.18 | N/A |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.66 | $5.90 |
| 52 Week High | $13.61 | $14.22 |
Technical Indicators
Market Signals| Indicator | VINP | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 42.68 |
| Support Level | $10.56 | $9.02 |
| Resistance Level | $10.87 | $14.03 |
| Average True Range (ATR) | 0.45 | 0.63 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 80.10 | 35.04 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.